<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01434914</url>
  </required_header>
  <id_info>
    <org_study_id>OCT-UKE-2011</org_study_id>
    <nct_id>NCT01434914</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy of Octenisept® in Patients With Chronic Wounds</brief_title>
  <official_title>Randomized, Double-blind, Single-center, Placebo-controlled Study to Evaluate the Efficacy of Octenisept® in Patients With Chronic Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Schülke &amp; Mayr GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Schülke &amp; Mayr GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled trial with octenisept® or placebo in
      patients with chronic leg ulcers. The study will be conducted at a single center with a total
      of 70 patients. Patients will be randomized to either the octenisept® group or to the placebo
      group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double-blind, placebo-controlled trial with octenisept® or placebo in patients
      with chronic leg ulcers. The study will be conducted at a single center with a total of 70
      patients. Patients will be randomized to either the octenisept® group or to the placebo
      group.

      Primary Objectives: Antimicrobial efficacy of octenisept® compared to placebo. Secondary
      Objectives: Subjective tolerance of octenisept®, evaluation of wound parameters.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    early termination due to poor recruitment
  </why_stopped>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antimicrobial efficacy of octenisept® compared to placebo</measure>
    <time_frame>2 weeks after baseline</time_frame>
    <description>Decrease of bacterial load after 2 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective tolerance of octenisept®</measure>
    <time_frame>2 weeks after baseline</time_frame>
    <description>Clinical signs of tolerance of octenisept®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of wound parameters</measure>
    <time_frame>2 weeks after baseline</time_frame>
    <description>Evaluation of wound healing time and wound size (Planimetry)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Ulcus Cruris</condition>
  <arm_group>
    <arm_group_label>verum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>octenisept®</intervention_name>
    <description>Cutaneous solution</description>
    <arm_group_label>verum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Cutaneous use</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients of at least 18 years at the time of consent

          -  Patients with a venous leg ulcer (Ulcus cruris)

          -  Patients with a chronic leg ulcer

          -  Females of childbearing potential who are willing to comply with any applicable
             contraceptive requirements of the protocol

          -  Negative pregnancy test

          -  Satisfactory medical assessment

          -  Ability to provide written informed consent

          -  Signed declaration of consent

          -  Willingness to co-operate

        Exclusion Criteria:

          -  Pregnant or lactating women and women not using contraception

          -  Known history of alcohol or drug abuse

          -  Use of any antibiotic medication within the last 7 days prior to the first dose

          -  Patients with serious concomitant disease

          -  Patients with a coagulation disorder

          -  Known history of allergic reactions attributed to octenisept® or one of its compounds

          -  Participation in another clinical trial within the last 30 days before randomization

          -  Concomitant treatment with other preparations that interfere with the trial
             preparation or the disease

          -  Absence of declaration of consent

          -  Doubt about willingness to co-operate

          -  Non-fulfilment of the inclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Augustin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.schuelke.com</url>
  </link>
  <reference>
    <citation>Vanscheidt W, Baer M, May TW, Siebert J.: Affecting the wound healing process of chronic ulcera by an octenidine based wound antiseptic. Hyg Med (2005) 30 (5): 153-8</citation>
  </reference>
  <reference>
    <citation>Hübner NO, Siebert J, Kramer A. Octenidine dihydrochloride, a modern antiseptic for skin, mucous membranes and wounds. Skin Pharmacol Physiol. 2010;23(5):244-58. doi: 10.1159/000314699. Epub 2010 May 18. Review.</citation>
    <PMID>20484966</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2011</study_first_submitted>
  <study_first_submitted_qc>September 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2011</study_first_posted>
  <last_update_submitted>May 12, 2014</last_update_submitted>
  <last_update_submitted_qc>May 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcus cruris</keyword>
  <keyword>chronic wounds</keyword>
  <keyword>octenisept®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octenidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

